Previous studies have demonstrated that botulinum toxin type A (BoNT-A) attenuates orofacial nociception. However, there has been no evidence of the participation of the voltage-gated sodium channels (Navs) in the antinociceptive mechanisms of BoNT-A. This study investigated the cellular mechanisms underlying the antinociceptive effects of BoNT-A in a male Sprague-Dawley rat model of trigeminal neuropathic pain produced by malpositioned dental implants. The left mandibular second molar was extracted under anesthesia, followed by a miniature dental implant placement to induce injury to the inferior alveolar nerve. Mechanical allodynia was monitored after subcutaneous injection of BoNT-A at 3, 7, or 12 d after malpositioned dental implant surgery. Subcutaneous injections of 1 or 3 U/kg of BoNT-A on postoperative day 3 significantly attenuated mechanical allodynia, although 0.3 U/kg of BoNT-A did not affect the air-puff threshold. A single injection of 3 U/kg of BoNT-A produced prolonged antiallodynic effects over the entire experimental period. Treatment with BoNT-A on postoperative days 7 and 12, when pain had already been established, also produced prolonged antiallodynic effects. Double treatments with 1 U/kg of BoNT-A produced prolonged, more antiallodynic effects as compared with single treatments. Subcutaneous administration of 3 U/kg of BoNT-A significantly inhibited the upregulation of Nav isoform 1.7 (Nav1.7) expression in the trigeminal ganglion in the nerve-injured animals. These results suggest that antinociceptive effects of BoNT-A are mediated by an inhibition of upregulated Nav1.7 expression in the trigeminal ganglion. BoNT-A is therefore a potential new therapeutic agent for chronic pain control, including neuropathic pain.
AhnDKLeeSYHanSRJuJSYangGYLeeMKYounDHBaeYC. 2009. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain. 146(1–2):114–120.
2.
Bach-RojeckyLReljaMLackovićZ.2005. Botulinum toxin type A in experimental neuropathic pain. J Neural Transm (Vienna). 112(2):215–219.
3.
BakerMDWoodJN. 2001. Involvement of Na+ channels in pain pathways. Trends Pharmacol Sci. 22(1):27–31.
4.
BorodicGEAcquadroMA. 2002. The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 3(1):21–27.
5.
CatterallWAGoldinALWaxmanSG. 2005. International Union of Pharmacology: XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 57(4):397–409.
6.
CuiMKhanijouSRubinoJAokiKR. 2004. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 107(1–2):125–133.
7.
CuratoloMPetersen-FelixSArendt-NielsenLGianiCZbindenAMRadanovBP. 2001. Central hypersensitivity in chronic pain after whiplash injury. Clin J Pain. 17(4):306–315.
Favre-GuilmardCAuguetMChabrierPE. 2009. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol. 617(1–3):48–53.
11.
GazeraniPStaahlCDrewesAMArendt-NielsenL.2006. The effects of botulinum toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 122(3):315–325.
12.
GöbelHHeinzeAHeinze-KuhnKAustermannK.2001. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 91(3):195–199.
HefferanMPO’RiellyDDLoomisCW. 2003. Inhibition of spinal prostaglandin synthesis early after L5/L6 nerve ligation prevents the development of prostaglandin-dependent and prostaglandin-independent allodynia in the rat. Anesthesiology. 99(5):1180–1188.
15.
HuangYZangYZhouLGuiWLiuXZhongY.2014. The role of TNF-alpha/NF-kappa B pathway on the up-regulation of voltage-gated sodium channel Nav1.7 in DRG neurons of rats with diabetic neuropathy. Neurochem Int. 75:112–119.
16.
IwataK. 2015. Mechanisms underlying orofacial extraterritorial pain in animal models of trigeminal neuropathic or inflammatory pain. Basic and clinical workshop presented at: Fifth International Congress on Neuropathic Pain; Nice, France.
17.
IwataKImaiTTsuboiYTashiroAOgawaAMorimotoTMasudaYTachibanaYHuJ.2001. Alteration of medullary dorsal horn neuronal activity following inferior alveolar nerve transection in rats. J Neurophysiol. 86(6):2868–2877.
18.
JabbariBMaherNDifazioMP. 2003. Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 4(2):206–210.
19.
JeonHJHanSRParkMKYangKYBaeYCAhnDK. 2012. A novel trigeminal neuropathic pain model: compression of the trigeminal nerve root produces prolonged nociception in rats. Prog Neuropsychopharmacol Biol Psychiatry. 38(2):149–158.
20.
KitamuraYMatsukaYSpigelmanIIshiharaYYamamotoYSonoyamaWKamiokaHYamashiroTKubokiTOgumaK.2009. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 159(4):1422–1429.
21.
KumadaAMatsukaYSpigelmanIMaruhamaKYamamotoYNeubertJKNolanTAWatanabeKMaekawaKKamiokaH. 2012. Intradermal injection of botulinum toxin type A alleviates infraorbital nerve constriction-induced thermal hyperalgesia in an operant assay. J Oral Rehabil. 39(1):63–72.
22.
LiuCCaoJRenXZangW.2012. Nav1.7 protein and mRNA expression in the dorsal root ganglia of rats with chronic neuropathic pain. Neural Regen Res. 7(20):1540–1544.
23.
LiuHTTsaiSKKaoMCHuJS. 2006. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 7(1):89–91.
24.
LuvisettoSMarinelliSCobianchiSPavoneF.2007. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience. 145(1):1–4.
25.
LuvisettoSMarinelliSLucchettiFMarchiFCobianchiSRossettoOMontecuccoCPavoneF.2006. Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res. 1082(1):124–131.
26.
MarbanEYamagishiTTomaselliGF. 1998. Structure and function of voltage-gated sodium channels. J Physiol. 508(Pt 3):647–657.
27.
McMahonHTForanPDollyJOVerhageMWiegantVMNichollsDG. 1992. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J Biol Chem. 267(30):21338–21343.
28.
MengJOvsepianSVWangJPickeringMSasseAAokiKRLawrenceGWDollyJO. 2009. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 29(15):4981–4992.
29.
MengJWangJLawrenceGDollyJO. 2007. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 120(Pt 16):2864–2874.
30.
ParkHJLeeYLeeJParkCMoonDE. 2006. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth. 53(5):470–477.
31.
PurkissJWelchMDowardSFosterK.2000. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol. 59(11):1403–1406.
32.
RanouxDAttalNMorainFBouhassiraD.2008. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 64(3):274–283. Erratum in Ann Neurol. 2009;65(3):359.
33.
ShinMCWakitaMXieDJYamagaTIwataSToriiYHarakawaTGinnagaAKozakiSAkaikeN.2012. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci. 118(1):33–42.
34.
StricklandITMartindaleJCWoodhamsPLReeveAJChessellIPMcQueenDS. 2008. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur J Pain. 12(5):564–572.
35.
ThalakotiSPatilVVDamodaramSVauseCVLangfordLEFreemanSEDurhamPL. 2007. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache. 47(7):1008–1023.
36.
TürkUIlhanSAlpRSurH.2005. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 28(4):161–162.
37.
VerdiJJafari-SabetMMokhtariRMesdaghiniaABanafsheHR. 2013. The effect of progesterone on expression and development of neuropathic pain in a rat model of peripheral neuropathy. Eur J Pharmacol. 699(1–3): 207–212.
38.
WaxmanSG. 2006. Neurobiology: a channel sets the gain on pain. Nature. 444(7121):831–832.
39.
WonKAKimMJYangKYParkJSLeeMKParkMKBaeYCAhnDK. 2014. The glial-neuronal GRK2 pathway participates in the development of trigeminal neuropathic pain in rats. J Pain. 15(3):250–261.
40.
YeomansDCLevinsonSRPetersMCKoszowskiAGTzabazisAZGillyWFWilsonSP. 2005. Decrease in inflammatory hyperalgesia by herpes vector-mediated knockdown of Nav1.7 sodium channels in primary afferents. Hum Gene Ther. 16(2):271–277.
41.
YoonSHMerrillRLChoiJHKimST. 2010. Use of botulinum toxin type A injection for neuropathic pain after trigeminal nerve injury. Pain Med. 11(4):630–632.
